The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of lazertinib in patients with epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
 
Min Hee Hong
Stock and Other Ownership Interests - GI biome; GI cell
Honoraria - AstraZeneca; AstraZeneca; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Merck; Roche; Yuhan
Research Funding - Yuhan
 
Yoon Ji Choi
No Relationships to Disclose
 
Hee Kyung Ahn
No Relationships to Disclose
 
Bhumsuk Keam
Honoraria - Lilly; Merck; Yuhan
Consulting or Advisory Role - CBS Bioscience; Handok; ImmuneOncia; NeoImmuneTech; Trial Informatics
Research Funding - AstraZeneca; MSD Oncology; Ono Pharmaceutical
 
Yu Jung Kim
No Relationships to Disclose
 
Ju Won Kim
No Relationships to Disclose
 
Hye Ryun Kim
Speakers' Bureau - Ono Pharmaceutical; Roche/Genentech
 
Jin-Hyoung Kang
No Relationships to Disclose